Document is current
Any future updates will be listed below
-
Authors
Chen, Hongze https://orcid.org/0000-0002-4805-4150
Nisar, Muhammad Azhar https://orcid.org/0000-0003-3249-6365
Mulla, Joud https://orcid.org/0000-0002-3872-0404
Li, Xinjian https://orcid.org/0009-0006-6407-0122
Cao, Kevin
Lu, Shaolei
Nagaoka, Katsuya https://orcid.org/0000-0002-7152-6101
Wu, Shang https://orcid.org/0009-0009-1870-4210
Ting, Peng-Sheng https://orcid.org/0000-0003-1581-2354
Tseng, Tung-Sung https://orcid.org/0000-0001-6266-9891
Lin, Hui-Yi
Yin, Xiao-Ming
Feng, Wenke
Wu, Zhijin https://orcid.org/0000-0002-9596-9134
Cheng, Zhixiang
Mueller, William
Bay, Amalia
Schechner, Layla https://orcid.org/0009-0003-6097-3963
Bai, Xuewei
Huang, Chiung-Kuei https://orcid.org/0000-0001-6331-7898
-
Funding
Funding for this research was provided by:
HHS | NIH | National Institute on Alcohol Abuse and Alcoholism (R21AA028576)
HHS | NIH | National Institute on Alcohol Abuse and Alcoholism (R01AA030424)
HHS | NIH | National Institute on Alcohol Abuse and Alcoholism (R01AA023190)
American Association for the Study of Liver Diseases (2017 AASLDF Pinnacle Research Development Award)
HHS | NIH | National Institute of General Medical Sciences (P20GM109035)
HHS | NIH | NIDDK | Division of Diabetes, Endocrinology, and Metabolic Diseases (DK135664)
- License Information
-
More Information
Article History
Received: 11 September 2024
Revised: 7 March 2025
Accepted: 12 March 2025
First Online: 31 March 2025
Disclosure and competing interests statement
: Dr. Xiao-Ming Yin is the Board of Advisor, NanoPin Technologies, New Orleans, LA. The NanoPin Technologies has no role in this study. All other authors have no competing interests.
